Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In CRC, Tregs situated in the tumor mesenchyme result in a better prognosis, whereas Tregs residing in the tumor nests and infiltrating margins are linked to unfavorable clinical outcomes [142, 143].”
From Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review (2024) · cites this paper as [142]
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
TNM Classification of Malignant Tumors
Carter, D. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199810000-00016 · Cited by 6,330
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TNM Classification of Malignant Tumours
(2003) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471463752 · Cited by 3,946
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., & Boon, T. (1991) · Science · doi:10.1126/science.1840703 · Cited by 3,545
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Research works printed but not linked: 3
- D. Pardoll, Nature411, 1010 (2001).
- Y. Naito et al., Cancer Res.58, 3491 (1998).
- We thank A. Rodi and M. Pelegrin for expert technical assistance; I. Gresser for helpful comments and critical review of the manuscript; and D. Frucht C. Anderson and T. Pokrovska for critically reading the manuscript. Supported by the Association pour la Recherche sur le Cancer (ARC) through the Alliance pour la Recherche sur le Cancer network (ARECA) INSERM Action Concertée Incitative ACI IMPBio Université Paris-Descartes Paris 5 and the Austrian Federal Ministry of Education Science and Culture (GBN-AU project Bioinformatics Integration Network).
Cited by
Items 901–1,000 of 1,043
Tumor‐infiltrating lymphocytes for the treatment of metastatic cancer
Geukes Foppen, M. H., Donia, M., Svane, I. M., & Haanen, J. B. A. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.018 · Cited by 131
Sharma, A., Bode, B., Wenger, R. H., Lehmann, K., Sartori, A. A., Moch, H., Knuth, A. K., von Boehmer, L., & van den Broek, M. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028217 · Cited by 146
Role of TH17 cytokines in the control of colorectal cancer
De Simone, V., Pallone, F., Monteleone, G., & Stolfi, C. (2013) · OncoImmunology · doi:10.4161/onci.26617 · Cited by 126
Zhang, Y., Luo, F., Cai, Y., Liu, N., Wang, L., Xu, D., & Chu, Y. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002320 · Cited by 145
Cancer Vaccines: A Brief Overview
Thomas, S., & Prendergast, G. C. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3387-7_43 · Cited by 145
Overman, M. J., Ernstoff, M. S., & Morse, M. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200821 · Cited by 130
Gide, T. N., da Silva, I. P., Quek, C. Y. J., Ahmed, T., Menzies, A. M., Carlino, M. S., Saw, R. P. M., Thompson, J. F., Batten, M., Long, G. V., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1659093 · Cited by 147
Liu, F., Qin, L., Liao, Z., Song, J., Yuan, C., Liu, Y., Wang, Y., Xu, H., Zhang, Q., Pei, Y., et al. (2020) · Experimental Hematology & Oncology · doi:10.1186/s40164-020-00165-3 · Cited by 126
The Abscopal Effect of Radiation Therapy
Craig, D. J., Nanavaty, N. S., Devanaboyina, M., Stanbery, L., Hamouda, D., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2021) · Future Oncology · doi:10.2217/fon-2020-0994 · Cited by 145
Abousamra, S., Gupta, R., Hou, L., Batiste, R., Zhao, T., Shankar, A., Rao, A., Chen, C., Samaras, D., Kurc, T., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.806603 · Cited by 84
T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control
Steele, M. M., Jaiswal, A., Delclaux, I., Dryg, I. D., Murugan, D., Femel, J., Son, S., du Bois, H., Hill, C. M., Leachman, S. A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01443-y · Cited by 146
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
Pancreatic adenocarcinomas with mature blood vessels have better overall survival
Katsuta, E., Qi, Q., Peng, X., Hochwald, S. N., Yan, L., & Takabe, K. (2019) · Scientific Reports · doi:10.1038/s41598-018-37909-5 · Cited by 146
Fully automated sequential immunofluorescence (seqIF) for hyperplex spatial proteomics
Rivest, F., Eroglu, D., Pelz, B., Kowal, J., Kehren, A., Navikas, V., Procopio, M. G., Bordignon, P., Pérès, E., Ammann, M., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-43435-w · Cited by 148
Jiang, Y., Xie, J., Han, Z., Liu, W., Xi, S., Huang, L., Huang, W., Lin, T., Zhao, L., Hu, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0848 · Cited by 143
“Given the major clinical importance of distinct tumor regions, it is appropriate to conduct immune cell infiltration evaluation systematically in the two separate areas, the CT and the IM (11, 12, 17).”
BackgroundResultPine, J. K., Morris, E. J. A., Hutchins, G. G. A., West, N. P., Jayne, D. G., Quirke, P., & Prasad, R. K. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.87 · Cited by 143
The many faces of Janus kinase
Seavey, M. M., & Dobrzański, P. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.024 · Cited by 143
Courau, T., Nehar-Belaid, D., Florez, L., Levacher, B., Vazquez, T., Brimaud, F., Bellier, B., & Klatzmann, D. (2016) · JCI Insight · doi:10.1172/jci.insight.85974 · Cited by 131
Marisa, L., Svrcek, M., Collura, A., Becht, E., Cervera, P., Wanherdrick, K., Buhard, O., Goloudina, A., Jonchère, V., Selves, J., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx136 · Cited by 127
Targeted drug delivery to melanoma
Liu, Q., Das, M., Liu, Y., & Huang, L. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.09.016 · Cited by 144
The dark side of tumor-associated endothelial cells
Sanctis, F. D., Ugel, S., Facciponte, J. G., & Facciabene, A. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.02.002 · Cited by 143
Infiltration of CD8 + T cells into tumor cell clusters in triple-negative breast cancer
Li, X., Gruosso, T., Zuo, D., Omeroglu, A., Meterissian, S., Guiot, M.-C., Salazar, A., Park, M., & Levine, H. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817652116 · Cited by 134
Tumour microenvironment responsive nanoconstructs for cancer theranostic
Gulzar, A., Xu, J., Wang, C., He, F., Yang, D., Gai, S., Yang, P., Lin, J., Jin, D., & Xing, B. (2019) · Nano Today · doi:10.1016/j.nantod.2019.03.007 · Cited by 139
Lugli, A., Karamitopoulou, E., Panayiotides, I., Karakitsos, P., Rallis, G., Peros, G., Iezzi, G., Spagnoli, G., Bihl, M., Terracciano, L., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605318 · Cited by 128
Ujiie, H., Kadota, K., Nitadori, J.-I., Aerts, J. G., Woo, K. M., Sima, C. S., Travis, W. D., Jones, D. R., Krug, L. M., & Adusumilli, P. S. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1009285 · Cited by 135
Predicting prognosis and therapeutic response from interactions between lymphocytes and tumor cells
Quigley, D. A., & Kristensen, V. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.003 · Cited by 133
Reyal, F., van Vliet, M. H., Armstrong, N. J., Horlings, H. M., de Visser, K. E., Kok, M., Teschendorff, A. E., Mook, S., Veer, L. V. ‘., Caldas, C., et al. (2008) · Breast Cancer Research · doi:10.1186/bcr2192 · Cited by 142
Scurr, M., Ladell, K., Besneux, M., Christian, A., Hockey, T., Smart, K., Bridgeman, H., Hargest, R., Phillips, S., Davies, M., et al. (2014) · Mucosal Immunology · doi:10.1038/mi.2013.62 · Cited by 127
Papavassiliou, A. G., & Musti, A. M. (2020) · Cells · doi:10.3390/cells9112470 · Cited by 143
Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer
Kießler, M., Plesca, I., Sommer, U. J., Wehner, R., Wilczkowski, F., Müller, L., Tunger, A., Lai, X., Rentsch, A., Peuker, K., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001813 · Cited by 143
Targeting the activity of T cells by membrane surface redox regulation for cancer theranostics
Shi, C., Zhang, Q., Yao, Y., Zeng, F., Du, C., Nijiati, S., Wen, X., Zhang, X., Yang, H., Chen, H., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01261-7 · Cited by 142
Efficient Treg depletion induces T‐cell infiltration and rejection of large tumors
Li, X., Kostareli, E., Suffner, J., Garbi, N., & Hämmerling, G. J. (2010) · European Journal of Immunology · doi:10.1002/eji.201041093 · Cited by 126
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma
Patschan, O., Sjödahl, G., Chebil, G., Lövgren, K., Lauss, M., Guðjónsson, S., Kollberg, P., Eriksson, P., Aine, M., Månsson, W., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.02.021 · Cited by 141
Ohnishi, K., Komohara, Y., Saito, Y., Miyamoto, Y., Watanabe, M., Baba, H., & Takeya, M. (2013) · Cancer Science · doi:10.1111/cas.12212 · Cited by 123
The Clinical Impact of the Genomic Landscape of Mismatch Repair–Deficient Cancers
Germano, G., Amirouchene-Angelozzi, N., Rospo, G., & Bardelli, A. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0150 · Cited by 128
Tumor-Associated Lymphatic Vessel Features and Immunomodulatory Functions
Garnier, L., Gkountidi, A.-O., & Hugues, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00720 · Cited by 120
Tumor-Altered Dendritic Cell Function: Implications for Anti-Tumor Immunity
Hargadon, K. M. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00192 · Cited by 141
Immune Escape Mechanisms in Colorectal Cancer Pathogenesis and Liver Metastasis
Pancione, M., Giordano, G., Remo, A., Febbraro, A., Sabatino, L., Manfrin, E., Ceccarelli, M., & Colantuoni, V. (2014) · Journal of Immunology Research · doi:10.1155/2014/686879 · Cited by 140
Yuan, Y. (2015) · Journal of The Royal Society Interface · doi:10.1098/rsif.2014.1153 · Cited by 125
Zheng, Z., Bu, Z., Liu, X., Zhang, L., Li, Z., Wu, A., Wu, X., Cheng, X., Xing, X., Du, H., et al. (2014) · Chinese Journal of Cancer Research · doi:10.3978/j.issn.1000-9604.2014.02.08 · Cited by 140
Lechner, A., Schlößer, H., Rothschild, S. I., Thelen, M., Reuter, S., Zentis, P., Shimabukuro-Vornhagen, A., Theurich, S., Wennhold, K., Garcia-Marquez, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17901 · Cited by 132
HBV induced hepatocellular carcinoma and related potential immunotherapy
Jia, L., Gao, Y., He, Y., Hooper, J. D., & Yang, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104992 · Cited by 140
Hindley, J. P., Ferreira, C., Jones, E., Lauder, S. N., Ladell, K., Wynn, K. K., Betts, G. J., Singh, Y., Price, D. A., Godkin, A. J., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-1797 · Cited by 118
Zaitsev, A., Chelushkin, M., Dyikanov, D., Cheremushkin, I., Shpak, B., Nomie, K., Zyrin, V., Nuzhdina, E., Lozinsky, Y., Zotova, A., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.07.006 · Cited by 139
Tumor-on-chip modeling of organ-specific cancer and metastasis
Del Piccolo, N., Shirure, V. S., Bi, Y., Goedegebuure, S. P., Gholami, S., Hughes, C. C. W., Fields, R. C., & George, S. C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.008 · Cited by 126
Invasive front of colorectal cancer: Dynamic interface ofpro-/anti-tumor factors
Zlobec, I., & Lugli, A. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.5898 · Cited by 139
Panis, C., Victorino, V. J., Herrera, A. C. S. A., Freitas, L. F., De Rossi, T., Campos, F. C., Simão, A. N. C., Barbosa, D. S., Pinge-Filho, P., Cecchini, R., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1851-1 · Cited by 138
“Despite clinical data supporting the idea that systemic Th1 responses inhibit human tumor growth and predict improved patient outcome [41], a fairly consist body of evidence demonstrates that Fig.”
BackgroundMacrophages limit chemotherapy
Palma, M. D., & Lewis, C. E. (2011) · Nature · doi:10.1038/472303a · Cited by 138
Feng, Z., Puri, S., Moudgil, T., Wood, W., Hoyt, C. C., Wang, C., Urba, W. J., Curti, B. D., Bifulco, C. B., & Fox, B. A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0091-z · Cited by 128
Treg Depletion Licenses T Cell–Driven HEV Neogenesis and Promotes Tumor Destruction
Colbeck, E. J., Jones, E., Hindley, J. P., Smart, K., Schulz, R., Browne, M., Cutting, S., Williams, A. S., Parry, L., Godkin, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0131 · Cited by 138
Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients
Xi, G., Guo, W., Kang, D., Ma, J., Fu, F., Qiu, L., Zheng, L., He, J., Fang, N., Chen, J., et al. (2021) · Theranostics · doi:10.7150/thno.55921 · Cited by 138
Teng, F., Mu, D., Meng, X., Kong, L., Zhu, H., Liu, S., Zhang, J., & Yu, J. (2015) · Europe PMC (PubMed Central) · Cited by 137
Zabijak, L., Attencourt, C., Guignant, C., Chatelain, D., Marcelo, P., Marolleau, J., & Treiner, E. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1764-7 · Cited by 136
Solomon, B., Young, R. J., Bressel, M., Urban, D., Hendry, S. A., Thai, A. A., Angel, C. M., Haddad, A., Kowanetz, M., Fua, T. F., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0299 · Cited by 137
Simula, L., Pacella, I., Colamatteo, A., Procaccini, C., Cancila, V., Bordi, M., Tregnago, C., Corrado, M., Pigazzi, M., Barnaba, V., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.11.018 · Cited by 129
Fuchs, T. L., Sioson, L., Sheen, A., Nejad, K. J., Renaud, C. J., Andrici, J., Ahadi, M. S., Chou, A. S. Y., & Gill, A. J. (2019) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001409 · Cited by 136
Lambin, P., Lieverse, R. I. Y., Eckert, F., Marcus, D., Oberije, C., van der Wiel, A. M.-M. A., Guha, C., Dubois, L. J., & Deasy, J. O. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.003 · Cited by 136
High endothelial venules in cancer: Regulation, function, and therapeutic implication
Vella, G., Hua, Y., & Bergers, G. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.002 · Cited by 138
Overcoming cold tumors: a combination strategy of immune checkpoint inhibitors
Ouyang, P., Wang, L., Wu, J., Tian, Y., Chen, C., Li, D., Yao, Z., Chen, R., Xiang, G., Gong, J., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1344272 · Cited by 137
Calabrò, A., Beißbarth, T., Kuner, R., Stojanov, M., Benner, A., Asslaber, M., Ploner, F., Zatloukal, K., Samonigg, H., Poustka, A., et al. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0105-3 · Cited by 136
Huang, Z.-L., Luo, J. P., Chen, M.-S., Li, J. Q., & Shi, M. (2011) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2010.12.041 · Cited by 135
Lin, A., Schildknecht, A., Nguyen, L. T., & Ohashi, P. S. (2009) · Immunology Letters · doi:10.1016/j.imlet.2009.09.003 · Cited by 135
Grossman, J. G., Nywening, T. M., Belt, B. A., Panni, R. Z., Krasnick, B. A., DeNardo, D. G., Hawkins, W. G., Goedegebuure, S. P., Linehan, D. C., & Fields, R. C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1470729 · Cited by 123
Pomatto-Watson, L. C. D., Bodogai, M., Bosompra, O., Kato, J., Wong, S., Carpenter, M., Duregon, E., Chowdhury, D., Krishna, P., Ng, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26431-4 · Cited by 118
Stachowiak, A. N., & Irvine, D. J. (2008) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.31661 · Cited by 122
Wu, X., Zhang, H.-B., Xing, Q. R., Cui, J., Li, J., Li, Y., Tan, Y. Q., & Wang, S. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.416 · Cited by 134
Prognostic value of tumour necrosis and host inflammatory responses in colorectal cancer
Richards, C. H., Roxburgh, C. S. D., Anderson, J. H., McKee, R. F., Foulis, A. K., Horgan, P. G., & McMillan, D. C. (2012) · Journal of British Surgery · doi:10.1002/bjs.7755 · Cited by 121
Microenvironment-Derived IL-1 and IL-17 Interact in the Control of Lung Metastasis
Carmi, Y., Rinott, G., Dotan, S., Elkabets, M., Rider, P., Voronov, E., & Apte, R. N. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002901 · Cited by 115
Berghoff, A. S., Ricken, G., Wilhelm, D., Rajky, O., Widhalm, G., Dieckmann, K. U., Birner, P., Bartsch, R., & Preusser, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2216-8 · Cited by 135
Morrot, A., da Fonseca, L. M., Salustiano, E. J., Gentile, L. B., Conde, L., Filardy, A. A., Franklim, T. N., da Costa, K. M., Freire-de-Lima, C. G., & Freire‐de‐Lima, L. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00081 · Cited by 134
Reichling, C., Taïeb, J., Dérangère, V., Klopfenstein, Q., Malicot, K. L., Gornet, J., Bécheur, H., Fein, F., Cojocarasu, O., Kaminsky, M. C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319292 · Cited by 134
The Immune System — is it Relevant to Cancer Development, Progression and Treatment?
Prestwich, R. J. D., Errington‐Mais, F., Hatfield, P., Merrick, A. E., Ilett, E. J., Selby, P. J., & Melcher, A. A. (2007) · Clinical Oncology · doi:10.1016/j.clon.2007.10.011 · Cited by 133
Tumor-Induced CD8+ T-Cell Dysfunction in Lung Cancer Patients
Prado-García, H., Romero‐Garcia, S., Aguilar‐Cázares, D., Meneses-Flores, M., & López-González, J. S. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/741741 · Cited by 133
Deep Learning Based Automatic Immune Cell Detection for Immunohistochemistry Images
Chen, T., & Chefd’hotel, C. (2014) · Lecture notes in computer science · doi:10.1007/978-3-319-10581-9_3 · Cited by 133
Kwak, Y., Koh, J., Kim, D., Kang, S., Kim, W. H., & Lee, H. S. (2016) · Oncotarget · doi:10.18632/oncotarget.13207 · Cited by 133
Banik, G. L., Betts, C. B., Liudahl, S. M., Sivagnanam, S., Kawashima, R., Cotechini, T., Larson, W., Goecks, J., Pai, S. I., Clayburgh, D. R., et al. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.039 · Cited by 133
CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma
Gu, Y., Li, X., Bi, Y., Zheng, Y., Wang, J., Li, X., Huang, Z., Chen, L., Huang, Y., & Huang, Y. (2020) · Aging · doi:10.18632/aging.102656 · Cited by 133
Yu, Q., Xia, Y., Lin, Z., Qu, Y., Qi, Y., Chen, Y., Zhou, Q., Zeng, H., Wang, J., Chang, Y., et al. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02563-2 · Cited by 133
Characteristics and significance of colorectal cancer associated lymphoid reaction
Väyrynen, J. P., Väyrynen, S. A., Klintrup, K., Mäkelä, J. T., Herzig, K., Karttunen, T. J., Tuomisto, A., & Mäkinen, M. J. (2013) · International Journal of Cancer · doi:10.1002/ijc.28533 · Cited by 133
Prostate cancer lesions are surrounded by FOXP3+, PD-1+ and B7-H1+ lymphocyte clusters
Ebelt, K., Babaryka, G., Frankenberger, B., Stief, C. G., Eisenmenger, W., Kirchner, T., Schendel, D. J., & Noeßner, E. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.02.015 · Cited by 133
Ascierto, P. A., Capone, M., Urba, W. J., Bifulco, C. B., Botti, G., Lugli, A., Marincola, F. M., Ciliberto, G., Galon, J., & Fox, B. A. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-54 · Cited by 120
Self-citationLiu, J. Y., Li, F., Wang, L. P., Chen, X. F., Wang, D., Cao, L., Ping, Y., Zhao, S., Li, B., Thorne, S. H., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.290 · Cited by 116
Zhao, J., Huang, W., Wu, Y., Luo, Y., Wu, B., Cheng, J., Chen, J., Liu, D., & Li, C. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1094-5 · Cited by 132
Immunogenic cell death in colon cancer prevention and therapy
Ruan, H., Leibowitz, B. J., Zhang, L., & Yu, J. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23183 · Cited by 132
Trial watch: Chemotherapy with immunogenic cell death inducers
Vacchelli, E., Galluzzi, L., Fridman, W. H., Galon, J., Sautès-Fridman, C., Tartour, E., & Kroemer, G. (2012) · OncoImmunology · doi:10.4161/onci.1.2.19026 · Cited by 115
Self-citationImmune checkpoint inhibitors for POLE or POLD1 proofreading-deficient metastatic colorectal cancer
Ambrosini, M., Rousseau, B., Manca, P., Artz, O., Marabelle, A., André, T., Maddalena, G., Mazzoli, G., Intini, R., Cohen, R., et al. (2024) · Annals of Oncology · doi:10.1016/j.annonc.2024.03.009 · Cited by 133
Colorectal cancer and immunity: What we know and perspectives
Pernot, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i14.3738 · Cited by 131
Lal, N., Beggs, A. D., Willcox, B. E., & Middleton, G. W. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.976052 · Cited by 112
Quantitative CD3 PET Imaging Predicts Tumor Growth Response to Anti-CTLA-4 Therapy
Larimer, B. M., Wehrenberg-Klee, E. P., Caraballo, A., & Mahmood, U. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.173930 · Cited by 131
The colorectal cancer immune microenvironment and approach to immunotherapies
Koi, M., & Carethers, J. M. (2017) · Future Oncology · doi:10.2217/fon-2017-0145 · Cited by 131
Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond
Cohen, R., Rousseau, B., Vidal, J., Colle, R., Diaz, L. A., & André, T. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00690-0 · Cited by 131
Siska, P. J., Singer, K., Evert, K., Renner, K., & Kreutz, M. (2020) · Immunological Reviews · doi:10.1111/imr.12846 · Cited by 123
Faget, J., Biota, C., Bachelot, T., Gobert, M., Treilleux, I., Goutagny, N., Durand, I., Léon-Goddard, S., Blay, J. Y., Caux, C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0573 · Cited by 129
STAT3, a master regulator of anti-tumor immune response
Rébé, C., & Ghiringhelli, F. (2019) · Cancers · doi:10.3390/cancers11091280 · Cited by 129
“Tumor-infiltrating CD4+ and CD8+ T-cells are associated with varying clinical outcomes and survival in many types of cancer such as colorectal, [22] breast [23] and lung cancers [24].”
BackgroundDushyanthen, S., Teo, Z. L., Caramia, F., Savas, P., Mintoff, C. P., Virassamy, B., Henderson, M. A., Luen, S. J., Mansour, M., Kershaw, M. H., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00728-9 · Cited by 124
Malesci, A., Bianchi, P., Celesti, G., Basso, G., Marchesi, F., Grizzi, F., Di Caro, G., Cavalleri, T., Rimassa, L., Palmqvist, R., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1342918 · Cited by 124
Guo, L., Wang, C., Qiu, X., Pu, X., & Chang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01052 · Cited by 122
“(17) CRC I–IV 75 Microarray analysis for genes”
BackgroundHypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Immune checkpoint inhibitors in cancer therapy
Eika, S., Peng, L., Renato, B., Nicholas, R., Ming, Y., & Yaohe, W. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.31.20160168 · Cited by 119
Role of Macrophages in Brain Tumor Growth and Progression
Guadagno, E., Presta, I., Maisano, D., Donato, A., Pirrone, C., Cardillo, G., Corrado, S., Mignogna, C., Mancuso, T., Donato, G., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041005 · Cited by 118
Metadata
- Authors
- Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., Zinzindohoué, F., Bruneval, P., Cugnenc, P.-H., Trajanoski, Z., Fridman, W.-H., & Pagès, F.
- Affiliations
- INSERM U 255, Paris, 75006 France; Université Paris-Descartes Paris 5, Faculté de Médecine, Paris, 75006 France; and Université Pierre et Marie Curie Paris 6, Institut des Cordeliers, Paris, 75006 France.
- Inserm (FR)
- ORCID
- Venue
- Science
- Published
- 2006-09-29
- Volume
- 313
- Issue
- 5795
- Pages
- 1960-1964
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2142300779
- Cited by
- 6,516
- References
- 31
- Citations by year
- 2026: 237 · 2025: 278 · 2024: 329 · 2023: 444 · 2022: 451 · 2021: 574 · 2020: 524 · 2019: 433 · 2018: 447 · 2017: 405 · 2016: 394 · 2015: 380 · 2014: 268 · 2013: 282 · 2012: 237
- FWCI
- 70.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, tumor-infiltrating immune cells, adaptive immune response, prognostic factors, patient survival, tumor immune microenvironment, gene expression profiling, cancer immunotherapy
- MeSH terms
- Female, Humans, Immunohistochemistry, Immunologic Memory, Lymphatic Metastasis, Male, Neoplasm Invasiveness, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Colorectal Neoplasms, Cohort Studies, Survival Analysis, Polymerase Chain Reaction, T-Lymphocyte Subsets, Lymphocytes, Tumor-Infiltrating, CD3 Complex, Leukocyte Common Antigens, CD8-Positive T-Lymphocytes, Th1 Cells, Disease Progression, Disease-Free Survival, Lymphocyte Count, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.